How is POLIVY thought to work?

POLIVY is a type of medicine called an antibody-drug conjugate, or ADC. POLIVY is designed to work differently from traditional chemotherapies because it has the ability to find dividing B cells, including cancerous B cells.

Almost all B cells (including cancerous ones) have a marker on their surface called CD79b. POLIVY works by finding and attaching to B cells using the CD79b marker before entering the cell and releasing an anti-cancer drug, killing the B cell. POLIVY may also harm healthy cells in your body.

*Antibodies are also produced naturally by the body. They are a type of protein that acts as a natural defense system against disease.

Who is POLIVY for?

POLIVY is an FDA-approved treatment for people with DLBCL who have already received at least 2 prior therapies. It is used in combination with 2 other cancer treatments: bendamustine and rituximab product. The approval of POLIVY is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of POLIVY.

Talk to your doctor about possible side effects. Please also see the full Prescribing Information for a complete list of possible side effects.